Eli Lilly (LLY) Stock Overview

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. More details

LLY fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	4/6
Past Performance	5/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 42.7% below our estimate of its fair value

Earnings are forecast to grow 16.62% per year

Earnings grew by 93.6% over the past year

Risk Analysis

Has a high level of debt

LLY Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW440,300 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

440,300 investors already sharing narratives

View all narratives

Eli Lilly and Company Competitors

Price History & Performance

Summary of share price highs, lows and changes for Eli Lilly
Historical stock prices
Current Share Price	US$920.00
52 Week High	US$1,010.00
52 Week Low	US$590.00
Beta	0.50
1 Month Change	-8.00%
3 Month Change	1.66%
1 Year Change	53.33%
3 Year Change	86.99%
5 Year Change	310.71%
Change since IPO	3,113.97%

Recent updates

Shareholder Returns

	LLY	CH Pharmaceuticals	CH Market
7D	-1.1%	-7.5%	-3.5%
1Y	53.3%	21.4%	11.0%

Return vs Industry: LLY exceeded the Swiss Pharmaceuticals industry which returned 21.4% over the past year.

Return vs Market: LLY exceeded the Swiss Market which returned 11% over the past year.

Price Volatility

Is LLY's price volatile compared to industry and market?
LLY volatility
LLY Average Weekly Movement	4.6%
Pharmaceuticals Industry Average Movement	4.4%
Market Average Movement	3.9%
10% most volatile stocks in CH Market	7.5%
10% least volatile stocks in CH Market	2.0%

Stable Share Price: LLY has not had significant price volatility in the past 3 months compared to the Swiss market.

Volatility Over Time: LLY's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1876	50,000	Dave Ricks	www.lilly.com

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin’s lymphoma; and Verzenio for breast cancer.

Eli Lilly and Company Fundamentals Summary

How do Eli Lilly's earnings and revenue compare to its market cap?
LLY fundamental statistics
Market cap	CHF 812.13b
Earnings (TTM)	CHF 21.81b
Revenue (TTM)	CHF 65.06b

37.2x

P/E Ratio

12.5x

P/S Ratio

Is LLY overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LLY income statement (TTM)
Revenue	US$79.67b
Cost of Revenue	US$13.23b
Gross Profit	US$66.44b
Other Expenses	US$39.73b
Earnings	US$26.71b

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

Oct 29, 2026

Earnings per share (EPS)	29.97
Gross Margin	83.40%
Net Profit Margin	33.53%
Debt/Equity Ratio	162.1%

How did LLY perform over the long term?

See historical performance and comparison

Dividends

0.6%

Current Dividend Yield

22%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/13 02:54
End of Day Share Price	2026/09/11 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Eli Lilly and Company is covered by 53 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
David Toung	Argus Research Company
Emily Field	Barclays
Kerry Holford	Berenberg

Eli Lilly (LLY) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Eli Lilly and Company Competitors

Roche Holding

Novartis

Galderma Group

Sandoz Group

Price History & Performance

Recent News & Updates

Eli Lilly and Company (NYSE:LLY) completed the acquisition of AtaiBeckley Inc. (NasdaqGM:ATAI) from Apeiron Investment Group Limited, BlackRock, Inc. (NYSE : BLK) and others.

Eli Lilly And Company Reports 52-Week Results From Together-PsO and TOGETHER-PSA Phase 3b Clinical Trials Evaluating Taltz And Zepbound Used Together in Adults with Psoriatic Disease and Obesity

Upcoming dividend of US$1.73 per share

Eli Lilly and Company Updates Earning Guidance for the Year 2026

Second quarter 2026 earnings released: EPS: US$7.94 (vs US$6.30 in 2Q 2025)

Eli Lilly and Company Receives Fda Breakthrough Therapy Designation for Olomorasib as Monotherapy for Previously Treated Kras G12c-Mutant Advanced Pancreatic Cancer

Recent updates

Eli Lilly and Company (NYSE:LLY) completed the acquisition of AtaiBeckley Inc. (NasdaqGM:ATAI) from Apeiron Investment Group Limited, BlackRock, Inc. (NYSE : BLK) and others.

Eli Lilly And Company Reports 52-Week Results From Together-PsO and TOGETHER-PSA Phase 3b Clinical Trials Evaluating Taltz And Zepbound Used Together in Adults with Psoriatic Disease and Obesity

Upcoming dividend of US$1.73 per share

Eli Lilly and Company Updates Earning Guidance for the Year 2026

Second quarter 2026 earnings released: EPS: US$7.94 (vs US$6.30 in 2Q 2025)

Eli Lilly and Company Receives Fda Breakthrough Therapy Designation for Olomorasib as Monotherapy for Previously Treated Kras G12c-Mutant Advanced Pancreatic Cancer

Eli Lilly and Company (NYSE:LLY) entered into an Agreement and Plan of Merger to acquire AtaiBeckley Inc. (NasdaqGM:ATAI) from Apeiron Investment Group Limited and others for $2.6 billion.

First quarter dividend of US$1.73 announced

Eli Lilly And Company Receives Positive Opinion From CHMP For Jaypirca For Treatment Of Adults With Chronic Lymphocytic Leukemia Across All Lines Of Therapy

Eli Lilly and Company (NYSE:LLY) completed the acquisition of Centessa Pharmaceuticals plc (NasdaqGS:CNTA) from Medicxi Ventures (UK) LLP, Index Ventures SA, General Atlantic Service Company, L.P. and other shareholders.

Eli Lilly and Company Declares Dividend for the Third Quarter of 2026, Payable on September 10, 2026

Eli Lilly and Company (NYSE:LLY) acquired 4E Therapeutics Inc.

Eli Lilly and Company Receives Fda Approval for EBGLYSS Maintenance Dose Every Eight Weeks in Patients with Moderate-To-Severe Atopic Dermatitis

Eli Lilly And Company Delivers Superior A1C Control And Weight Loss With Foundayo In Three Pivotal Type 2 Diabetes Trials

Eli Lilly And Company Announces Results From Phase 3 LIBRETTO-432 Clinical Trial Of Retevmo (Selpercatinib) As Adjuvant Therapy Versus Placebo In Patients With Early-Stage RET Fusion-Positive Non-Small Cell Lung Cancer

Eli Lilly and Company Presents New Data on Foundayo, Mounjaro and Retatrutide At the American Diabetes Association's 86Th Scientific Sessions

Eli Lilly and Company Announces Expanded Coverage for Foundayo and Zepbound Obesity Medicines

Eli Lilly and Company (NYSE:LLY) entered into an agreement to acquire Curevo, Inc. from HBM Healthcare Investments AG (SWX:HBMN), a fund managed by HBM Partners Ltd., and others for $1.5 billion.

Eli Lilly and Company Showcases Oncology Portfolio Across Tumor Types and Treatment Modalities At the American Society of Clinical Oncology Annual Meeting

Eli Lilly and Company Announces Results of Retatrutide Phase 3 Clinical Trial

Walden Macht Haran & Williams LLP Secures Victory Against Eli Lilly and Company

Insufficient new directors

Eli Lilly and Company Presents Results for Foundayo and Zepbound in Weight Loss Maintenance Trials

First quarter dividend of US$1.73 announced

Eli Lilly and Company Announces Omvoh Demonstrates Durable Disease Clearance in Ulcerative Colitis Through Four Years

Eli Lilly and Company Raises Earning Guidance for the Year 2026

First quarter 2026 earnings released: EPS: US$8.26 (vs US$3.07 in 1Q 2025)

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire remaining majority stake in Ajax Therapeutics, Inc. for $2.3 billion.

Insufficient new directors

Lilly Reportedly in Advanced Talks to Acquire Kelonia Therapeutics for over $2 Billion

Eli Lilly and Company Announces Positive Topline Results from Phase 3 Achieve-4 Trial Evaluating Foundayo (Orforglipron) Compared to Insulin Glargine in Adults with Type 2 Diabetes and Obesity or Overweight At Increased Cardiovascular Risk

Eli Lilly And Company Announces Positive Phase 3 Results For Jaypirca (Pirtobrutinib) In Previously Treated CLL/SLL

Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S

Eli Lilly And Company Receives FDA Approval For Foundayo (Orforglipron) For Weight Loss

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Centessa Pharmaceuticals plc (NasdaqGS:CNTA) from Medicxi Ventures (UK) LLP, Index Ventures SA, General Atlantic Service Company, L.P. and other shareholders for $5.6 billion.

Eli Lilly and Company Presents Phase 3B Data on Taltz and Zepbound Combination for Adults with Psoriatic Arthritis and Obesity

Eli Lilly And Company Delivers Durable Disease Control With Ebglyss For Moderate-To-Severe Atopic Dermatitis

Eli Lilly And Company Demonstrates Significant Reductions In A1C And Weight With Retatrutide In First Phase 3 Trial For Treatment Of Type 2 Diabetes

Eli Lilly And Company Announces Positive Phase 3 Results For EBGLYSS In Pediatric Patients With Moderate-To-Severe Atopic Dermatitis

Eli Lilly and Company, Annual General Meeting, May 04, 2026

Takeda Pharmaceuticals USA, Inc., Takeda Pharmaceutical Company Limited and Eli Lilly and Company Announce National Third-Party Payor Class Certified in Lawsuit Regarding Actos

Eli Lilly and Company Launches Employer Connect Platform with Tailored Obesity Coverage Options

Insufficient new directors

Eli Lilly and Company's Olumiant Recommends by CHMP for Approval of Expanded Use in the European Union for Adolescents with Severe Alopecia Areata

Eli Lilly and Company Announces Detailed Results from ACHIEVE-3

Eli Lilly and Company Announces the U.S. Food and Drug Administration Approves a Label Expansion for Zepbound® (tirzepatide)

Eli Lilly and Company Presents New Long-Term Data from Eli Lilly and Company's Omvoh (mirikizumab-mrkz)

Eli Lilly and Company Announces Positive Topline Results from Taltz (Ixekizumab) and Zepbound (Tirzepatide)

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 LIBRETTO-432 Clinical Trial of Retevmo

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Orna Therapeutics, Inc. in a transaction valued at $2.4 billion.

Upcoming dividend of US$1.73 per share

Full year 2025 earnings released: EPS: US$22.95 (vs US$11.76 in FY 2024)

Eli Lilly and Company Provides Earnings Guidance for the Full Year 2026

Third quarter dividend of US$1.73 announced

Insufficient new directors

Eli Lilly and Company to Report Q4, 2025 Results on Feb 04, 2026

Eli Lilly and Company's Sofetabart Mipitecan Receives U.S. FDA's Breakthrough Therapy Designation for the Treatment of Certain Patients with Platinum-Resistant Ovarian Cancer

Strive Compounding Pharmacy Files Landmark Antitrust Lawsuit Against Eli Lilly and Novo Nordisk

Eli Lilly and Company Announces Positive Topline Results from the Novel TOGETHER-PsA Open-Label Phase 3b Trial Evaluating the Concomitant Use of Taltz (Tirzepatide)

Eli Lilly and Company (NYSE:LLY) entered into an Agreement and Plan of Merger to acquire Ventyx Biosciences, Inc. (NasdaqGS:VTYX) from New Science Ventures, LLC and others for approximately $1 billion.

Ventyx Biosciences Reportedly in $1 Billion Acquisition Talks with Eli Lilly

Third quarter dividend of US$1.73 announced